Chimeric Immunogenic Polypeptides for Ehrlichia Detection and Vaccination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and vaccinating against Ehrlichia chaffeensis and Ehrlichia canis are limited due to the small repertoire of immunoreactive/protective proteins and the difficulty in defining antigens that provide effective immune responses in both extracellular and intracellular environments.
Innovation Solution
Development of chimeric immunogenic peptides and polypeptides composed of contiguously repeated immunogenic sequences from Ehrlichia species, which are verified to elicit significant immune responses and can be used in diagnostic methods or to induce immune responses against these pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional diagnostic and vaccination methods are used against Ehrlichia species, then the approach is simple and well-established, but the repertoire of immunoreactive proteins is limited and immune responses are insufficient in both extracellular and intracellular environments
Solution Approach 1:
The patent combines multiple immunogenic sequences from different Ehrlichia proteins into a single chimeric polypeptide structure. This merging of sequences (e.g., OMP, TRP, and other immunoreactive regions) creates a multifunctional antigen that can elicit broader immune responses against both extracellular and intracellular stages of the pathogen, thereby resolving the limitation of having a restricted repertoire of protective proteins.
Solution Approach 2:
The chimeric polypeptide functions as a composite immunogenic material, integrating multiple antigenic determinants from different Ehrlichia proteins into one molecular entity. This composite structure provides diverse epitopes that can be recognized by antibodies and T cells in different microenvironments, enhancing adaptability without requiring separate vaccines for different stages of infection.
2Reliability
If a small repertoire of immunoreactive proteins is used, then the vaccine and diagnostic design is straightforward, but the ability to define antigens that provide effective immune responses in both extracellular and intracellular environments is limited
Solution Approach 1:
The chimeric polypeptide is designed to perform multiple functions simultaneously: it serves as both a diagnostic antigen and a vaccine antigen, and it targets both extracellular and intracellular pathogen stages. By incorporating sequences from OMP (outer membrane protein) and TRP (tandem repeat protein) along with other immunoreactive regions, the single chimeric construct achieves universal applicability across different infection contexts, improving reliability without requiring multiple separate agents.
3Productivity
If contiguous repetition of immunogenic sequences is implemented, then immune response induction is significantly improved, but the polypeptide construction becomes more complex
Solution Approach 1:
The chimeric polypeptide is constructed by segmenting and repeating key immunogenic motifs (such as TRP tandem repeats and OMP epitopes) in a controlled manner. This segmentation allows the polypeptide to present multiple copies of critical epitopes to the immune system, enhancing immunogenicity through repeated exposure to the same antigenic determinants, while the modular nature of the construction facilitates rational design despite the increased complexity.
Data Source
AI summary
Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.